Sherlock Biosciences
Improving health worldwide through accurate, fast and affordable diagnostic testing
Improving health worldwide through accurate, fast and affordable diagnostic testing
Sherlock Biosciences is a biotechnology startup with a mission to revolutionize molecular diagnostics by providing accurate, fast, and affordable testing solutions. Their innovative Engineering Biology platforms are poised to address a wide array of challenges, including rapid pathogen detection, simplified cancer testing, and enhanced food safety. Their vision encompasses a world where their products empower users to make more informed decisions across various environments, from hospitals to home settings.
The company, founded in 2019, boasts a team and founders comprised of renowned experts in CRISPR, Synthetic Biology, and the diagnostic industry, alongside authorities in disease areas. This collective expertise positions Sherlock Biosciences at the forefront of transforming molecular diagnostics in both clinical and non-clinical settings.
Notably, the startup garnered significant attention with its most recent grant investment on 29 November 2022 from none other than the Bill & Melinda Gates Foundation, aligning with its aim to improve health globally. Located in the United States, Sherlock Biosciences stands as a compelling venture in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 |
|
29 Nov 2022 |
| Series B | $80.00M | 6 |
|
08 Mar 2022 |
| Venture Round | $1.98M | 1 | Alameda Research | 01 Jan 2022 |
| Grant | $7.50M | 1 | Open Philanthropy | 21 May 2020 |
| Series A | $31.00M | 3 |
|
23 Apr 2019 |
No recent news or press coverage available for Sherlock Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
